cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Pulmonx Corp
4 watching
Current Price
$9.02
$0.21
(2.38%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
337.42M
52-Week High
52-Week High
29.25
52-Week Low
52-Week Low
4.07
Average Volume
Average Volume
0.31M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization337.42M
icon52-Week High29.25
icon52-Week Low4.07
iconAverage Volume0.31M
iconDividend Yield--
iconP/E Ratio--
What does the Pulmonx Corp do?
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Read More
How much money does Pulmonx Corp make?
News & Events about Pulmonx Corp.
Ticker Report
10days ago
Pulmonx Co. (NASDAQ:LUNG Get Rating) has earned a consensus rating of Hold from the seven analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and ...
Ticker Report
30days ago
Pulmonx (NASDAQ:LUNG Get Rating) had its price objective lowered by Morgan Stanley from $14.00 to $9.50 in a report issued on Friday, Benzinga reports. The firm currently has an equal weight rating on the stock. Morgan Stanleys price target points to a potential upside ...
Globe Newswire
3 months ago
REDWOOD CITY, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx), a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming investor conferences in New York. Pulmonx management is ...
Business Wire
5 months ago
Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx), a global leader in minimally invasive treatments for severe lung disease, announces the presentation of interim results from the CONVERT Study at the 2022 European Respiratory Society (ERS) International Conference. Data on the first 40 patients in the...
Ticker Report
6 months ago
Pulmonx (NASDAQ:LUNG Get Rating) had its price target cut by Canaccord Genuity Group from $34.00 to $31.00 in a report issued on Thursday, The Fly reports. They currently have a buy rating on the stock. LUNG has been the topic of several other research reports. Morgan Stanley boosted their ...
Frequently Asked Questions
Frequently Asked Questions
What is Pulmonx Corp share price today?
plus_minus_icon
Can Indians buy Pulmonx Corp shares?
plus_minus_icon
How can I buy Pulmonx Corp shares from India?
plus_minus_icon
Can Fractional shares of Pulmonx Corp be purchased?
plus_minus_icon
What are the documents required to start investing in Pulmonx Corp stocks?
plus_minus_icon
What is today’s traded volume of Pulmonx Corp?
plus_minus_icon
What is today’s market capitalisation of Pulmonx Corp?
plus_minus_icon
What is the 52-Week High and Low Range of Pulmonx Corp?
plus_minus_icon
What percentage is Pulmonx Corp down from its 52-Week High?
plus_minus_icon
What percentage is Pulmonx Corp up from its 52-Week Low?
plus_minus_icon
Current Price
$9.02
$0.21
(2.38%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Valneva SE
Valneva SE
$14.29
$0.18 (1.28 %)
Zomedica Corp
Zomedica Corp
$0.28
$0.00 (0.89 %)
Fusion Pharmaceuticals Inc
Fusion Pharmaceuticals Inc
$3.35
$0.09 (2.76 %)
Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc.
$4.00
$0.54 (15.61 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Valneva SE
Valneva SE
$14.29
$0.18 (1.28 %)
Zomedica Corp
Zomedica Corp
$0.28
$0.00 (0.89 %)
Fusion Pharmaceuticals Inc
Fusion Pharmaceuticals Inc
$3.35
$0.09 (2.76 %)
Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc.
$4.00
$0.54 (15.61 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00